Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- CTI BioPharma
- Registration Number
- NCT00054210
- Locations
- 🇺🇸
Clinical Trials and Research Associates, Incorporated, Montebello, California, United States
🇺🇸Omni Healthcare, PA, Melbourne, Florida, United States
🇺🇸Columbia Comprehensive Cancer Care Clinic, Columbia, Missouri, United States
Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT00054028
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 144
- Registration Number
- NCT00040794
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00006004
- Locations
- 🇵🇪
Instituto de Enfermedades Neoplasicas, Lima, Peru
🇺🇸Mercy Medical Center, Des Moines, Iowa, United States
🇺🇸Iowa Methodist Medical Center, Des Moines, Iowa, United States
Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- University of California, Davis
- Registration Number
- NCT00009776
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 108
- Registration Number
- NCT00002558
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 800
- Registration Number
- NCT00002894
- Locations
- 🇬🇧
Middlesex Hospital- Meyerstein Institute, London, England, United Kingdom
Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 25
- Registration Number
- NCT00004077
- Locations
- 🇬🇧
Velindre Hospital, Cardiff, Wales, United Kingdom
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00005847
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸Veterans Affairs Medical Center - Atlanta (Decatur), Decatur, Georgia, United States
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 65
- Registration Number
- NCT00022633
- Locations
- 🇺🇸
Mobile Infirmary Medical Center, Mobile, Alabama, United States
🇺🇸Holland Community Hospital, Holland, Michigan, United States
🇺🇸Munson Medical Center, Traverse City, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.